Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis (original) (raw)

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

…, 2007

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Garth Ringheim

Frontiers in Immunology, 2021

View PDFchevron_right

Specific Btk inhibition suppresses B cell–and myeloid cell–mediated arthritis

Vincent Hurez

Nature Chemical …, 2010

View PDFchevron_right

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

Padmaja Magadala

Arthritis Research & Therapy, 2011

View PDFchevron_right

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development

Adam Johnson

Journal of medicinal chemistry, 2018

View PDFchevron_right

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Ewa Robak

Journal of Clinical Medicine

View PDFchevron_right

Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis

George Kalliolias

Clinical Immunology, 2013

View PDFchevron_right

Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

Karin Reif

Journal of Pharmacology and Experimental Therapeutics, 2011

View PDFchevron_right

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

Naiyu Zheng

Journal of Medicinal Chemistry

View PDFchevron_right

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Stephen White

The Journal of Immunology, 2021

View PDFchevron_right

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Jose Gómez-puerta

Current Topics in Medicinal Chemistry, 2013

View PDFchevron_right

Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis

David Fox

New England Journal of Medicine, 2012

View PDFchevron_right

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

Tamsin Lindstrom

Nature reviews. Rheumatology, 2009

View PDFchevron_right

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

Poonam Giri

Pharmacology Research & Perspectives, 2020

View PDFchevron_right

A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

Tamsin Lindstrom

Rheumatic diseases clinics of North America, 2010

View PDFchevron_right

Selective Tyrosine Kinase Inhibition By Imatinib As a Novel Treatment Strategy for Rheumatoid Arthritis

Peggy Ho

Clinical Immunology, 2006

View PDFchevron_right

The Importance of Bruton Tyrosine Kinase (BTK) and Targeted Therapies

Denise Jackson

Hematology & Transfusion International Journal, 2016

View PDFchevron_right

Ibrutinib and novel BTK inhibitors in clinical development

Nikhil Mukhi

Journal of Hematology & Oncology, 2013

View PDFchevron_right

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis

Allan Wissner

Bioorganic & Medicinal Chemistry Letters, 2011

View PDFchevron_right

Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile

Allard Kaptein

Journal of Pharmacology and Experimental Therapeutics

View PDFchevron_right

Dual Targeting of Janus Kinase and Bruton’s Tyrosine Kinase: A New Approach to Control the Pathogenesis of Rheumatoid Arthritis

Fatima Ijaz

Pakistan Journal of Zoology, 2020

View PDFchevron_right

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Igor Mochalkin

Journal of Medicinal Chemistry, 2019

View PDFchevron_right

The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner

Bernd Kinzel

The Journal of Immunology, 2011

View PDFchevron_right

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

Douglas Hough

Rheumatology and Therapy

View PDFchevron_right

Novel Bruton's tyrosine kinase inhibitors currently in development

Osmond D'Cruz

OncoTargets and Therapy, 2013

View PDFchevron_right

The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib

Gabriella meszaros

Clinical and experimental rheumatology, 2019

View PDFchevron_right

Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis

Lijun Xin

International Immunopharmacology, 2019

View PDFchevron_right

Second-Generation Brutons Tyrosine Kinase Inhibitors

SArmen Sarkissian

2017

View PDFchevron_right

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis (original) (raw)

Related papers